Cardiac resynchronization therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(76 intermediate revisions by 9 users not shown)
Line 1: Line 1:
{{SI}}
__NOTOC__
{| class="infobox" style="float:right;"
|-
| [[File:Siren.gif|30px|link= Congestive heart failure resident survival guide]]|| <br> || <br>
| [[Acute decompensated heart failure resident survival guide|'''Resident'''<br>'''Survival'''<br>'''Guide''']]
|}
{| class="infobox" style="float:right;"
|-
| [[File:Critical_Pathways.gif|88px|link= Congestive heart failure critical pathways]]|| <br> || <br>
|}
{{Cardiac resynchronization therapy}}
{{CMG}}; {{AOEIC}}: Bhaskar Purushottam, M.D. [mailto:bpurushottam@gmail.com]


{{CMG}}
{{SK}} CRT


==Indications==
==[[Cardiac resynchronization therapy overview|Overview]]==
The ACC / AHA guidelines indicate that CRT is recommended for those patients with all of the following: <ref name="pmid18483207">{{cite journal |author=Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA, Freedman RA, Gettes LS, Gillinov AM, Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page RL, Schoenfeld MH, Silka MJ, Stevenson LW, Sweeney MO, Smith SC, Jacobs AK, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Faxon DP, Halperin JL, Hiratzka LF, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura RA, Ornato JP, Page RL, Riegel B, Tarkington LG, Yancy CW |title=ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons |journal=[[Circulation]] |volume=117 |issue=21 |pages=e350–408 |year=2008 |month=May |pmid=18483207 |doi=10.1161/CIRCUALTIONAHA.108.189742 |url=http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=18483207 |issn= |accessdate=2011-01-15}}</ref>
* An [[LVEF]] ≤35 percent
* A [[QRS]] duration  ≥120 msec
* NYHA functional class III or ambulatory class IV symptoms  with optimal medical therapy


==References==
==[[Cardiac resynchronization therapy indications|Indications]]==
{{reflist|2}}
: [[Cardiac resynchronization therapy landmark trials|Landmark Trials]]
:'''[[Cardiac resynchronization therapy special populations|Special Populations]]''': [[Cardiac resynchronization therapy special populations#Atrial Fibrillation and CRT|Atrial Fibrillation Patients]] | [[Cardiac resynchronization therapy special populations#Cardiac Resynchronization Therapy in Minimal Heart Failure|Minimal Heart Failure Patients]]


{{WH}}
==[[Cardiac resynchronization therapy contraindications|Contraindications]]==
{{WS}}
 
==[[Cardiac resynchronization therapy pathophysiology|Pathophysiologic Basis For CRT]]==
 
==[[Cardiac resynchronization therapy procedure|Procedure]]==
 
==[[Cardiac resynchronization therapy prognosis|Outcomes and Prognosis]]==
 
==[[Cardiac resynchronization therapy complications|Complications]]==
 
==Related Chapters==
* [[Congestive heart failure]]
 
[[Category:Cardiology]]
[[Category:Disease]]
[[Category:Emergency medicine]]
[[Category:Intensive care medicine]]
[[Category:Medicine]]
[[Category:Up-To-Date]]
[[Category:Up-To-Date cardiology]]

Latest revision as of 14:12, 19 September 2021